Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2016, Article ID 7461783, 6 pages
http://dx.doi.org/10.1155/2016/7461783
Clinical Study

Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity

1Division of Pediatric Hematology/Oncology, Department of Pediatrics, Comprehensive Cancer Center Munich, Kinderklinik München Schwabing, Klinikum Rechts der Isar, Technische Universität München, München, Germany
2Department of Pediatric Hematology and Oncology, University Children’s Hospital Muenster, Muenster, Germany
3University of Antwerp, Antwerp University Hospital, Wilrijkstraat 10, 2650 Edegem, Belgium
4Department of Oncology, Laboratory of Cancer Pharmacology, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
5Department of Pediatrics, Van Andel Institute, Helen DeVos Children’s Hospital and Michigan State University, Grand Rapids, MI, USA
6Department of Medicine A, Hematology and Oncology, University of Muenster, Muenster, Germany

Received 16 June 2016; Revised 4 September 2016; Accepted 29 September 2016

Academic Editor: R. Lor Randall

Copyright © 2016 J. Herzog et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

J. Herzog, F. von Klot-Heydenfeldt, S. Jabar, et al., “Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity,” Sarcoma, vol. 2016, Article ID 7461783, 6 pages, 2016. https://doi.org/10.1155/2016/7461783.